SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 07, 2012 08:20 ET

Faster Approval Process Contributing to Biotech Industry's Success in 2012

The Paragon Report Provides Stock Research on Peregrine Pharmaceuticals and Repros Therapeutics

NEW YORK, NY--(Marketwire - Sep 7, 2012) - Despite concerns of a global economic slowdown the Biotech Industry has impressed investors with strong gains in 2012. Patent expirations, favorable legislation, and a faster review process have been some of the contributing factors for the industry's current boom. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Peregrine Pharmaceuticals (NASDAQ: PPHM) and Repros Therapeutics Inc. (NASDAQ: RPRX).

Access to the full company reports can be found at:

www.ParagonReport.com/PPHM

www.ParagonReport.com/RPRX

The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law on July 9, 2012 by President Obama. The law allows the FDA to collect "user fees" to help fund reviews of innovator drugs, medical devices, generic drugs and biosimilars.

"The legislation will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will also increase the Food and Drug Administration's (FDA) access to external expertise to improve the drug review process," Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood said in a statement.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara. They will report financial results for the first quarter of the fiscal year 2013 on September 10, 2012.

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. The company recently reported that the FDA provided guidance for a Phase 2 study of low dose oral Proellex in the treatment of endometriosis. Shares of the company have nearly tripled this year.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

http://www.paragonreport.com/disclaimer